Former Seattle Mariners’ second baseman Robinson Cano has tested positive for a P.E.D. for the second time. That will pretty much end his chances of making the Hall of Fame.
Former Mariners superstar Robinson Cano has now tested positive for a performance-enhancing drug for the second time in his career, which warrants a 162 game suspension and a surrender of pay for the time missed. This means Cano will miss out on all of his potential earnings in 2021 from his contract with the Mets which was supposed to be $24 million.
Cano was traded to the New York Mets by the Mariners during the 2018 offseason after missing half of that season for testing positive for a PED for the first time in his career. Edwin Diaz was sent to New York as well and the return looked like, and now looks even more like, a steal as the Mariners received Jarred Kelenic and Justin Dunn.
This time around, Cano tested positive for stanozolol, a synthetic steroid derived from testosterone that does what you would imagine a steroid does to help the body. Because of this second suspension, Cano will now certainly miss out on the Hall of Fame.
While the Hall of Fame voters have shown no remorse for steroid users which means testing twice is like running one of them over with a car, then backing up and doing it again, and then asking them to vote for them, Cano also will likely miss out on some milestones that he would have shared with various Hall of Famer’s.
Cano is 376 hits away from 3,000, 29 doubles away from 600 which only 17 players have reached, and his career WAR of 68.9 sits just below the second base Hall of Famer’s average of 69.5. Cano also has Hall of Fame anecdotes like 8-time All-Star, 2-time Gold Glove, 5-time Silver Slugger, and one time World Series champion.
Cano was a superstar with the Yankees and continued his stardom in Seattle making 3 All-Star teams. However, after this news and being a part of a lopsided deal that fans love to point at and laugh at, Cano’s legacy in Seattle, and in general, will forever be looked at unfavorably.